CUTISS announces positive one year data for denovoSkin
15-02-2024 – Cutiss has published the results of a one-year study on its skin alternative denovoSkin. The data from the Phase 2 clinical trial in adult and adolescent severe burn patients are positive. (Image credit: Swisstrade / CUTISS AG)
Cutiss AG, which specializes in skin grafts, has announced positive data from the one-year Phase 2 clinical trial of its lead product denovoSkin in adult and adolescent patients with severe burns. Following the positive primary endpoint in the first quarter of 2023, the one-year study evaluated the long-term safety and quality of the scars, according to a statement.
The article first appear on Swisstrade.
